Vu A. Vo - Publications

Drug repositioning of regorafenib for renal cell carcinoma identifies DDR2‑associated sensitivity in ACHN models.

Journal: The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Published: September 20, 2025

Etoposide-induced protein 2.4 homolog promotes argininosuccinate synthase 1 and cancer cell survival upon arginine deprivation.

Journal: Cellular & molecular biology letters

Published: November 28, 2024

Humanin activates integrin αV-TGFβ axis and leads to glioblastoma progression.

Journal: Cell death & disease

Published: August 21, 2023

Iron commensalism of mesenchymal glioblastoma promotes ferroptosis susceptibility upon dopamine treatment.

Journal: Communications biology

Published: August 04, 2021

Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.

Journal: Experimental & molecular medicine

Published: October 17, 2019

Correction: PPARγ sumoylation-mediated lipid accumulation in lung cancer.

Journal: Oncotarget

Published: March 13, 2019

Inhibition of oncogenic Src induces FABP4-mediated lipolysis via PPARγ activation exerting cancer growth suppression.

Journal: EBioMedicine

Published: November 20, 2018

PPARgamma-mediated ALDH1A3 suppression exerts anti-proliferative effects in lung cancer by inducing lipid peroxidation.

Journal: Journal of receptor and signal transduction research

Published: June 07, 2018

TRAP1 Inhibition Increases Glutamine Synthetase Activity in Glutamine Auxotrophic Non-small Cell Lung Cancer Cells.

Journal: Anticancer research

Published: January 31, 2018

PPARγ sumoylation-mediated lipid accumulation in lung cancer.

Journal: Oncotarget

Published: April 18, 2017

Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.

Journal: Oncotarget

Published: April 27, 2016